Released : March 31, 2017 12:40 RNS Number : 1963B MaxCyte, Inc. 31 March 2017 THIS ANNOUNCEMENT (INCLUDING ITS APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS (AS
Released : March 31, 2017 07:00 RNS Number : 0996B MaxCyte, Inc. 31 March 2017 THIS ANNOUNCEMENT (INCLUDING ITS APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS (AS
Released : March 20, 2017 07:00 RNS Number : 8799Z MaxCyte, Inc. 20 March 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2016 Consistent top-line growth with 32% increase in revenues and gross margins approaching 90% Maryland,
Released : January 24, 2017 07:00 RNS Number : 9020U MaxCyte, Inc. 24 January 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Consecutive 30 percent year-on year revenue growth Maryland, USA - 24 January 2017: MaxCyte (LSE: MXCT), the developer and supplier of cell
Released : January 03, 2017 14:49 RNS Number : 2281T MaxCyte, Inc. 03 January 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Issue of Equity from exercise of Share Options Maryland, USA -03 January 2017: MaxCyte (LSE: MXCT) announces the issue and allotment of 18,293 new shares of
Released : December 06, 2016 09:34 RNS Number : 0823R MaxCyte, Inc. 06 December 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Issue of Equity from exercise of Share Options Maryland, USA - 06 December 2016: MaxCyte (LSE: MXCT), announces the issue and allotment of 12,805 new
Released : October 21, 2016 07:43 RNS Number : 1438N MaxCyte, Inc. 21 October 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Driector/PDMR Sharedealing Maryland, USA - 21 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based medicines,
Released : September 28, 2016 18:00 RNS Number : 1371L MaxCyte, Inc. 28 September 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Gaithersburg, MD , 28 September 2016 - MaxCyte (LSE: MXCT) , an established and revenue generating US-based developer and supplier of cell
Released : September 27, 2016 07:00 RNS Number : 8786K MaxCyte, Inc. 27 September 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Financial Results for the Six Months ended 30 June 2016 Maryland, USA - 27 September - MaxCyte, Inc. (LSE: MXCT) , an established and revenue generating
